Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Chunjiang Wang, Yulu Zhou, Ya Zhou & Chao Ye. (2023) Ertapenem-Induced Neurotoxicity: A Literature Review of Clinical Characteristics and Treatment Outcomes. Infection and Drug Resistance 16, pages 3649-3658.
Read now
Read now
Gavin Matthew Joynt, Lowell Ling, Wai Tat Wong & Jeffrey Lipman. (2023) Therapeutic drug monitoring of carbapenem antibiotics in critically ill patients: an overview of principles, recommended dosing regimens, and clinical outcomes. Expert Review of Clinical Pharmacology 16:8, pages 703-714.
Read now
Read now
Santiago Grau, Virginia Lozano, Amparo Valladares, Rafael Cavanillas, Yang Xie & Gonzalo Nocea. (2014) Antibiotic expected effectiveness and cost under real life microbiology: evaluation of ertapenem and ceftriaxone in the treatment of community-acquired pneumonia for elderly patients in Spain. ClinicoEconomics and Outcomes Research 6, pages 83-92.
Read now
Read now
Itzhak Brook. (2011) Antimicrobial treatment of anaerobic infections. Expert Opinion on Pharmacotherapy 12:11, pages 1691-1707.
Read now
Read now
Ilias I Siempos, Argyris Michalopoulos & Matthew E Falagas. (2009) Treatment of acute bacterial exacerbations of chronic bronchitis. Expert Opinion on Pharmacotherapy 10:7, pages 1173-1182.
Read now
Read now
Jomy Joseph & Keith A Rodvold. (2008) The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opinion on Pharmacotherapy 9:4, pages 561-575.
Read now
Read now
Itzhak Brook. (2007) Treatment of anaerobic infection. Expert Review of Anti-infective Therapy 5:6, pages 991-1006.
Read now
Read now
Articles from other publishers (35)
Xuechun Li, Wenjing Le, Xiangdi Lou, Caroline A. Genco, Peter A. Rice & Xiaohong Su. (2022)
In Vitro
Activity of Ertapenem against Neisseria gonorrhoeae Clinical Isolates with Decreased Susceptibility or Resistance to Extended-Spectrum Cephalosporins in Nanjing, China (2013 to 2019)
. Antimicrobial Agents and Chemotherapy 66:5.
Crossref
Crossref
Jaruratanasirikul Sutep, Nopparatana Napawadee, Boonpeng Apinya, Sriwiriyajan Somchai, Kaewpratum Natruethai, Samaeng Maseetoh & Nawakitrangsan Monchana. (2021) NONMEM population pharmacokinetic and Monte Carlo dosing simulation of ertapenem in patients with sepsis. African Journal of Pharmacy and Pharmacology 15:4, pages 71-83.
Crossref
Crossref
Donald J. AbrahamSebastian A. Testero, Leticia I. Llarrull, Jed F. Fisher & Shahriar Mobashery. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
188
.
Wasim S. El Nekidy, Hazem Elrefaei, Terrence J. Lee St. John, Nizar M. Attallah, Farah Kablaoui, Ahmad Nusair, Bartlomiej Piechowski-Jozwiak, Janise Phillips & Islam M. Ghazi. (2020) Ertapenem Neurotoxicity in Hemodialysis Patients—Safe and Effective Dosing Is Still Needed: A Retrospective Study and Literature Review. Annals of Pharmacotherapy 55:1, pages 52-58.
Crossref
Crossref
Fernando García‐Souto, Sandra Cases‐Mérida, Francisco Sosa‐Moreno & Jerónimo Escudero‐Ordoñez. (2019) Ertapenem‐induced vasculitis with striking targetoid lesions. International Journal of Dermatology 59:2.
Crossref
Crossref
Yune-Fang Ueng, Hong-Jaan Wang, Shiao-Chi Wu & Yee-Yung Ng. (2019) A Thrice-Weekly Ertapenem Regimen Is Practical for Hemodialysis Patients. Antimicrobial Agents and Chemotherapy 63:12.
Crossref
Crossref
Pedro Sanroma, Pedro Muñoz, Manuel Mirón-Rubio, Ana Aguilera, Oriol Estrada, Dora García, Víctor J González-Ramallo, Marcos Pajarón, Giusi A Sgaramella, Carmen R González, Abel Mujal, Aquilino Abad, Anna Solé, Soledad González, Carmen Escalada, Isabel Vitoria, María J Gómez, Juan J Parra, Isabel Sampedro & Iliana Pereda. (2018) Effectiveness and safety of ertapenem used in hospital-at-home units: data from Spanish Outpatient Parenteral Antimicrobial Therapy Registry. Future Microbiology 13:12, pages 1363-1373.
Crossref
Crossref
Mathias Wittau, Stephan Paschke, Max Kurlbaum, Jan Scheele, Neang S. Ly, Evelyn Hemper, Marko Kornmann, Doris Henne-Bruns & Jürgen B. Bulitta. (2017) Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery. Antimicrobial Agents and Chemotherapy 61:1.
Crossref
Crossref
Mark A. Baker, Elena K. Schneider, Johnny X. Huang, Matthew A. Cooper, Jian Li & Tony Velkov. (2016) The Plasma Protein Binding Proteome of Ertapenem: A Novel Compound-Centric Proteomic Approach for Elucidating Drug–Plasma Protein Binding Interactions. ACS Chemical Biology 11:12, pages 3353-3364.
Crossref
Crossref
Sander P. van Rijn, Richard van Altena, Onno W. Akkerman, Dick van Soolingen, Tridia van der Laan, Wiel C.M. de Lange, Jos G.W. Kosterink, Tjip S. van der Werf & Jan-Willem C. Alffenaar. (2016) Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. European Respiratory Journal 47:4, pages 1229-1234.
Crossref
Crossref
Priyanka Ballal & Suneel Mundkur. (2016) A Brief Review of Ertapenem and Its Utility in Pediatric Patients. Pediatric Oncall 13:3.
Crossref
Crossref
K.-H. Lee, Y.-F. Ueng, C.-W. Wu, Y.-C. Chou, Y.-Y. Ng & W.-C. Yang. (2015) The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in haemodialysis patients - case reports and literature reviews. Journal of Clinical Pharmacy and Therapeutics 40:2, pages 240-244.
Crossref
Crossref
Jami G. Jain, Christina Sutherland, David P. Nicolau & Joseph L. Kuti. (2014) Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and −20 °C. American Journal of Health-System Pharmacy 71:17, pages 1480-1484.
Crossref
Crossref
Rachel F. Eyler, A. Mary Vilay, Ahmed M. Nader, Michael Heung, Melissa Pleva, Kevin M. Sowinski, Daryl D. DePestel, Fritz Sörgel, Martina Kinzig & Bruce A. Mueller. (2014) Pharmacokinetics of Ertapenem in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis or Hemodiafiltration. Antimicrobial Agents and Chemotherapy 58:3, pages 1320-1326.
Crossref
Crossref
Dora E. Wiskirchen, Seth T. Housman, Richard Quintiliani, David P. Nicolau & Joseph L. Kuti. (2013) Comparative Pharmacokinetics, Pharmacodynamics, and Tolerability of Ertapenem 1 Gram/Day Administered as a Rapid 5‐Minute Infusion versus the Standard 30‐Minute Infusion in Healthy Adult Volunteers. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:3, pages 266-274.
Crossref
Crossref
이유림, 오정미, 이혜숙, 김향숙, 이소영 & 조윤희. (2013) Drug Use Evaluation of Ertapenem. Journal of Korean Society of Health-System Pharmacists 30:1, pages 34-42.
Crossref
Crossref
Magnus UnemoRobert A Nicholas. (2012) Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiology 7:12, pages 1401-1422.
Crossref
Crossref
Fekade Bruck Sime, Michael S Roberts, Sandra L Peake, Jeffrey Lipman & Jason A Roberts. (2012) Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Annals of Intensive Care 2:1.
Crossref
Crossref
Magnus Unemo, Daniel Golparian, Athena Limnios, David Whiley, Makoto Ohnishi, Monica M. Lahra & John W. Tapsall. (2012)
In Vitro
Activity of Ertapenem versus Ceftriaxone against Neisseria gonorrhoeae Isolates with Highly Diverse Ceftriaxone MIC Values and Effects of Ceftriaxone Resistance Determinants: Ertapenem for Treatment of Gonorrhea?
. Antimicrobial Agents and Chemotherapy 56:7, pages 3603-3609.
Crossref
Crossref
Yun-Jeong Kim, Song-Hee Han, Ji-Young Jeon, Min-Ho Hwang, Yong-Jin Im, Soo-Wan Chae & Min-Gul Kim. (2012) Validation of LC-MS/MS method for determination of ertapenem in human plasma and urine. Analytical Science and Technology 25:1, pages 19-24.
Crossref
Crossref
Yi-Tzu Lee, Te-Li Chen, Leung-Kei Siu, Chien-Pei Chen & Chang-Phone Fung. (2011) Impact of Derepressed AmpC β-Lactamase ACT-9 on the Clinical Efficacy of Ertapenem. Antimicrobial Agents and Chemotherapy 55:9, pages 4440-4442.
Crossref
Crossref
Douglas C. Wu, Wilson W. Chan, Andrei I. Metelitsa, Loretta Fiorillo & Andrew N. Lin. (2011) Pseudomonas Skin Infection. American Journal of Clinical Dermatology 12:3, pages 157-169.
Crossref
Crossref
Travis W Cooper, Steven E Pass, Sara D Brouse & Ronald G HallIIII. (2017)
Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant
Acinetobacter
?
. Annals of Pharmacotherapy 45:2, pages 229-240.
Crossref
Crossref
Debra A Goff. (2011) Antimicrobial stewardship: bridging the gap between quality care and cost. Current Opinion in Infectious Diseases 24:Suppl 1, pages S11-S20.
Crossref
Crossref
Donald J. AbrahamSebastian A. Testero, Jed F. Fisher & Shahriar Mobashery. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
257
402
.
V. Cattoir & C. Daurel. (2010) Quelles nouveautés en antibiothérapie ?. Médecine et Maladies Infectieuses 40:3, pages 135-154.
Crossref
Crossref
Denis Frasca, Sandrine Marchand, Franck Petitpas, Claire Dahyot-Fizelier, William Couet & Olivier Mimoz. (2010) Pharmacokinetics of Ertapenem following Intravenous and Subcutaneous Infusions in Patients. Antimicrobial Agents and Chemotherapy 54:2, pages 924-926.
Crossref
Crossref
Ashwin Algudkar, Gidon Ellis, Fareeduddin Ahmad & Hilary Tindall. (2010) Prolonged Use of Ertapenem to Treat Infected Diabetic Foot Ulcers. Case Reports in Medicine 2010, pages 1-4.
Crossref
Crossref
Olaf Burkhardt, Vipul Kumar, Stephan Schmidt, Jan T. Kielstein, Tobias Welte & Hartmut Derendorf. (2010) Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations. International Journal of Antimicrobial Agents 35:1, pages 96-97.
Crossref
Crossref
Pavani Reddy, Smitha Chadaga & Gary A. Noskin. (2009) Antibiotic considerations in the treatment of multidrug‐resistant (MDR) pathogens: A case‐based review. Journal of Hospital Medicine 4:6.
Crossref
Crossref
A.J. Brink, G.A. Richards, V. Schillack, S. Kiem & J. Schentag. (2009) Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. International Journal of Antimicrobial Agents 33:5, pages 432-436.
Crossref
Crossref
S.James Matthews & Jason W. Lancaster. (2009) Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clinical Therapeutics 31:1, pages 42-63.
Crossref
Crossref
Francesco Scaglione & Luca Paraboni. (2008) Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. International Journal of Antimicrobial Agents 32:4, pages 294-301.e7.
Crossref
Crossref
O. Burkhardt, C. Hafer, A. Langhoff, V. Kaever, V. Kumar, T. Welte, H. Haller, D. Fliser & J. T. Kielstein. (2008) Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrology Dialysis Transplantation 24:1, pages 267-271.
Crossref
Crossref
Itzhak Brook. 2007. Anaerobic Infections. Anaerobic Infections
387
406
.